戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 d lymphocyte-dependent colitis, seronegative ankylosing arthritis and enthesitis, conditions stereoty
2 ythematosus (1346+/-1011 pg per milliliter), ankylosing spondylitis (1368+/-1162 pg per milliliter),
3  improved significantly after MR imaging for ankylosing spondylitis (29% vs 80%, P < .001), undiffere
4 ren of women had an even higher incidence of ankylosing spondylitis (7.2 [1.5-34], p=0.013) than did
5 ot disease and valve disease associated with ankylosing spondylitis (AKS).
6 systemic lupus erythematosus (SLE) (n = 10), ankylosing spondylitis (AS) (n = 10), primary Sjogren's
7                                              Ankylosing spondylitis (AS) affects 0.25-1.0% of the pop
8 s detailing their application in a number of ankylosing spondylitis (AS) and axial spondyloarthritis
9 mography (MDCT) findings of 41 patients with ankylosing spondylitis (AS) and compared them with pulmo
10 e autoimmune inflammatory arthritis disorder ankylosing spondylitis (AS) and with other related spond
11                Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are chronic inflammatory dis
12 ) affects approximately 40% of patients with ankylosing spondylitis (AS) but also affects patients wi
13 nk/ank mouse develops a phenotype similar to ankylosing spondylitis (AS) in humans.
14 tients with MRI-evident sacroiliitis develop ankylosing spondylitis (AS) in the long term and whether
15                                              Ankylosing spondylitis (AS) is a chronic inflammatory ar
16                                              Ankylosing spondylitis (AS) is a common and highly famil
17                                              Ankylosing spondylitis (AS) is a common, highly heritabl
18            We investigated the proposal that ankylosing spondylitis (AS) is associated with unusual E
19                                              Ankylosing spondylitis (AS) may present with extra-artic
20                     The clinical response in ankylosing spondylitis (AS) patients treated with biolog
21 ment of spinal inflammation in patients with ankylosing spondylitis (AS) relies primarily on magnetic
22 udies of the HLA-B27-transgenic rat model of ankylosing spondylitis (AS) suggested that macrophages d
23       A strong association between ERAP1 and ankylosing spondylitis (AS) was recently identified by t
24 7 subtypes associated with susceptibility to ankylosing spondylitis (AS), and those reported not to b
25 HC) tag SNPs from 1,000 independent cases of ankylosing spondylitis (AS), autoimmune thyroid disease
26 s I molecule B27 is strongly associated with ankylosing spondylitis (AS), but the pathogenic role of
27 rated high heritability of susceptibility to ankylosing spondylitis (AS), it is only recently that th
28 ld standard of rheumatologists' diagnosis of ankylosing spondylitis (AS), psoriatic arthritis (PsA),
29 l and peripheral articular manifestations of ankylosing spondylitis (AS), psoriatic arthritis (PsA),
30 endoplasmic reticulum aminopeptidase 1) with ankylosing spondylitis (AS), which is restricted to HLA-
31 l disease with rheumatoid arthritis (RA) and ankylosing spondylitis (AS).
32 lity of life (HRQOL) in patients with active ankylosing spondylitis (AS).
33 pathogenic role in the spondylarthropathy of ankylosing spondylitis (AS).
34  sulfapyridine (SP), in patients with active ankylosing spondylitis (AS).
35 e treatment of osteoporosis in patients with ankylosing spondylitis (AS).
36 ss I molecules due to their association with Ankylosing Spondylitis (AS).
37 hat is necessary to establish a diagnosis of ankylosing spondylitis (AS).
38 graphic damage in patients with longstanding ankylosing spondylitis (AS).
39 ciated with the chronic inflammatory disease Ankylosing Spondylitis (AS); however, the mechanisms und
40                                ASsessment of Ankylosing Spondylitis (ASAS) International Working Grou
41 D16S516), multiple sclerosis (D12S1052), and ankylosing spondylitis (D16S516).
42 = 8), juvenile rheumatoid arthritis (n = 3), ankylosing spondylitis (n = 1), and psoriatic spondylart
43 d IL12B regions convincingly associated with ankylosing spondylitis (P < 5 x 10(-8) in the combined d
44 tients with presumed sarcoidosis compared to ankylosing spondylitis (p = 0.0001), behcet's disease (p
45 ts with presumed sarcoidosis with respect to ankylosing spondylitis (p = 0.0001), behcet's disease, (
46 IBD), and psoriasis, psoriatic arthritis, or ankylosing spondylitis (psoriasis and spondyloarthropath
47 ges of patients achieving the Assessments in Ankylosing Spondylitis 20% response (ASAS20) at weeks 12
48        Reactive arthritis, sacroiliitis, and ankylosing spondylitis also appear to be increased in th
49  residues 528 and 575/725 is associated with ankylosing spondylitis among HLA-B27-positive individual
50 riteria for PsA, a new composite measure for ankylosing spondylitis and axial SpA, the ASDAS, new mea
51 ndyloarthropathic changes closely resembling ankylosing spondylitis and DISH.
52 dies of various physical therapy programs in ankylosing spondylitis and identify their benefits and p
53 has supported novel roles for these drugs in ankylosing spondylitis and in cancer prevention, accumul
54 ecent studies indicate that the morbidity of ankylosing spondylitis and PsA are considerably higher t
55                  Three risk loci shared with ankylosing spondylitis and psoriasis (the MHC class I re
56 uding rheumatoid arthritis, Crohn's disease, ankylosing spondylitis and psoriasis, confirms the impor
57 clude rheumatoid arthritis, Crohn's disease, ankylosing spondylitis and psoriasis.
58 immune-mediated disorders, most notably with ankylosing spondylitis and psoriasis.
59  of the tumor necrosis factor antagonists in ankylosing spondylitis and psoriatic arthritis has gener
60 necrosis factor inhibitors for patients with ankylosing spondylitis and psoriatic arthritis has had a
61    Sulfasalazine is moderately effective for ankylosing spondylitis and psoriatic arthritis, although
62       The greatest experience has accrued in ankylosing spondylitis and psoriatic arthritis.
63 ved functional status and quality of life in ankylosing spondylitis and psoriatic arthritis.
64 als with tumor necrosis factor inhibitors in ankylosing spondylitis and psoriatic arthritis.
65  are effective and safe for the treatment of ankylosing spondylitis and psoriatic arthritis.
66  cells from healthy donors and patients with ankylosing spondylitis and psoriatic arthritis.
67                                              Ankylosing spondylitis and related spondylarthritides ar
68 ole for HLA-B27 in genetic susceptibility to ankylosing spondylitis and related spondyloarthropathies
69                 Patients with juvenile-onset ankylosing spondylitis appear to have poorer functional
70 or rheumatoid arthritis, where patients with ankylosing spondylitis are offered therapy early in the
71 cant reductions in the signs and symptoms of ankylosing spondylitis at week 16.
72 e for relieving the pain of axial disease in ankylosing spondylitis but these findings contradict two
73 me-wide association study in 2,053 unrelated ankylosing spondylitis cases among people of European de
74  replication in an independent cohort of 898 ankylosing spondylitis cases and 1,518 controls.
75  changes in the course of the disease, Stoke Ankylosing spondylitis classification Spinal Score (SASS
76 oth M-CSF and MMP-3 correlated with the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) v
77 onset, disease activity assessed by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI),
78 ondylitis Functional Index (BASFI), the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI),
79 cal disease activity as measured by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI),
80 Disease activity was assessed using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI).
81 ter disease activity as measured by the Bath Ankylosing Spondylitis Disease Activity Index (P = 0.002
82 nthesitis (using the PsA-modified Maastricht Ankylosing Spondylitis Enthesitis Score [MASES] index).
83 ose with psoriatic arthritis, and those with ankylosing spondylitis from phase III trials of golimuma
84 al assessments included the BASDAI, the Bath Ankylosing Spondylitis Functional Index (BASFI), the Ank
85 ght, VAS scores for entheseal pain, the Bath Ankylosing Spondylitis Functional Index (BASFI), the Bat
86 d functional impairment assessed by the Bath Ankylosing Spondylitis Functional Index (BASFI).
87 nal limitations were assessed using the Bath Ankylosing Spondylitis Functional Index (BASFI; score ra
88 etween inflammation and structural damage in ankylosing spondylitis has been an important focus of re
89                           Medical therapy of ankylosing spondylitis has improved dramatically with th
90 ive arthritis, but an infectious trigger for ankylosing spondylitis has not yet been established.
91 d for patients with rheumatoid arthritis and ankylosing spondylitis have been reported, and generic q
92 at has been shown to control the symptoms of ankylosing spondylitis in a phase 2 trial.
93 x in determining increased susceptibility to ankylosing spondylitis in children.
94  that TNFi slows radiographic progression in ankylosing spondylitis in data from clinical trials may
95 osome regions in human genome, which control ankylosing spondylitis in human patients.
96 irst published clinical account of a case of ankylosing spondylitis in the United States.
97 f Life (ASQoL) instrument, the ASsessment in Ankylosing Spondylitis International Working Group crite
98                                              Ankylosing spondylitis is a common form of inflammatory
99                                              Ankylosing spondylitis is a genetically determined and c
100                                              Ankylosing spondylitis is an inflammatory autoimmune dis
101                                              Ankylosing spondylitis is associated with increased risk
102  IL-1A association further substantiate that ankylosing spondylitis is determined to a large extent b
103 modified New York criteria, the diagnosis of ankylosing spondylitis is made based on the presence of
104         Nearly half of the susceptibility to ankylosing spondylitis is provided by major histocompati
105       One of the major goals of treatment of ankylosing spondylitis is to prevent or slow the develop
106  autoimmune disease and evidence showed that ankylosing spondylitis may be a microbiome-driven diseas
107 dation of two new genes, IL23R and ARTS1, in ankylosing spondylitis pathogenesis.
108  shown to be differentially abundant between ankylosing spondylitis patients and healthy controls.
109                            A recent trial in ankylosing spondylitis patients demonstrated continuous
110                            Specifically, the ankylosing spondylitis patients demonstrated increases i
111 monly used in probiotics, accumulated in the ankylosing spondylitis patients.
112 emic sclerosis patients and in 3 of 12 (25%) ankylosing spondylitis patients.
113 ng Spondylitis Functional Index (BASFI), the Ankylosing Spondylitis Quality of Life (ASQoL) instrumen
114  the Short Form 36 (SF-36) Health Survey and Ankylosing Spondylitis Quality of Life (ASQoL) Questionn
115 tis Disease Activity Index (BASDAI), and the Ankylosing Spondylitis Quality of Life (ASQoL) questionn
116 lvis, and hips were scored by using the Bath Ankylosing Spondylitis Radiology Index (BASRI) by an exp
117 pinal radiographs were scored using the Bath Ankylosing Spondylitis Radiology Index for the spine (BA
118 dy reports four genetic loci associated with ankylosing spondylitis risk and identifies a major role
119 before HLA class I presentation, only affect ankylosing spondylitis risk in HLA-B27-positive individu
120 ) a random sample of members of the National Ankylosing Spondylitis Society.
121 bar spine, which were scored using the Stoke Ankylosing Spondylitis Spine Score.
122  of the interleukin-1 (IL-1) region genes in ankylosing spondylitis suggested the susceptibility to b
123 A recent meta-analysis of published scans of ankylosing spondylitis susceptibility has confirmed site
124 on-major histocompatibility complex genes in ankylosing spondylitis susceptibility, and suggests area
125 ocompatibility complex), 10q, 16q and 19q in ankylosing spondylitis susceptibility.
126 nt GWAS on multiple sclerosis, psoriasis and ankylosing spondylitis that inclusion of known covariate
127 ide strong evidence that HLA-B27 operates in ankylosing spondylitis through a mechanism involving abe
128 Exercise therapy should remain a mainstay of ankylosing spondylitis treatment complementing medical t
129 durations may result in a paradigm shift for ankylosing spondylitis treatment similar to that undergo
130                                              Ankylosing spondylitis was more prevalent among children
131  50% and 75% of patients were diagnosed with ankylosing spondylitis were ascertained from a database
132     Forty patients with active, inflammatory ankylosing spondylitis were randomly assigned to receive
133 cantly reduces spinal inflammation in active ankylosing spondylitis when compared to placebo; there w
134 esitis-related arthritis progress to develop ankylosing spondylitis within 10 years after presentatio
135              The spondylarthritides (such as ankylosing spondylitis) are multisystem inflammatory dis
136 e SpA (2 with psoriatic arthritis and 1 with ankylosing spondylitis) were isolated by positive select
137 une hemolytic anemia, pernicious anemia, and ankylosing spondylitis), infectious (pneumonia, hepatiti
138  relationship between the gut microbiome and ankylosing spondylitis, a quantitative metagenomics stud
139  Evaluating Long-Term Efficacy and Safety in Ankylosing Spondylitis, a randomized controlled study, w
140  patients with systemic lupus erythematosus, ankylosing spondylitis, and hepatic fibrosis.
141 anding inflammation in rheumatoid arthritis, ankylosing spondylitis, and juvenile chronic arthritis.
142 tion may have structure-modifying effects in ankylosing spondylitis, and may thereby alter the diseas
143 immune diseases such as behcet's disease and ankylosing spondylitis, and ocular involvement of infect
144 nvestigated one in detail, a risk allele for ankylosing spondylitis, and provide direct evidence of a
145 py not only in RA but also in Crohn disease, ankylosing spondylitis, and several other chronic inflam
146 lgia rheumatica (PMR), giant cell arteritis, ankylosing spondylitis, and Sjogren's syndrome, and to p
147 e of the spondyloarthritides, including PsA, ankylosing spondylitis, and the broader categories of Sp
148 the disease-modifying role of these drugs in ankylosing spondylitis, and their use in the understudie
149 s, two patients with gout, two patients with ankylosing spondylitis, and two patients with psoriatic
150              This group includes 6 entities: ankylosing spondylitis, arthritis associated with inflam
151 h American sample of two new loci related to ankylosing spondylitis, ARTS1 and IL23R, and confirmatio
152  a prospective study involving patients with ankylosing spondylitis, behcet's disease, presumed sarco
153 eously investigated the genetic landscape of ankylosing spondylitis, Crohn's disease, psoriasis, prim
154 0 patients and 45 controls: alopecia areata, ankylosing spondylitis, dermatomyositis, Graves' disease
155 ce of rheumatoid arthritis, Crohn's disease, ankylosing spondylitis, familial Mediterranean fever, an
156 esitis in psoriatic arthritis and uveitis in ankylosing spondylitis, have also been observed.
157  principle has relevance to diseases such as ankylosing spondylitis, in which HLA-B27 and ERAP jointl
158 , rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-infectious uveitis, and mult
159 d arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, or inflammatory bowel disease us
160 e advances in the pharmacological therapy of ankylosing spondylitis, physical therapy remains an esse
161 carrying of the spinal cord in the course of ankylosing spondylitis, present in MRI include: bone mar
162 n the pathogenesis or development process of ankylosing spondylitis, providing new leads for the deve
163  Group criteria for SpA, without evidence of ankylosing spondylitis, psoriasis, inflammatory bowel di
164 ct in the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and juvenil
165 ts and for diseases other than RA, including ankylosing spondylitis, psoriatic arthritis, and polymyo
166 uded in the category of spondyloarthropathy (ankylosing spondylitis, psoriatic arthritis, reactive ar
167 ry rheumatic diseases that primarily include ankylosing spondylitis, reactive arthritis, and the arth
168  rheumatological conditions (i.e. psoriasis, ankylosing spondylitis, rheumatoid arthritis, fibromyalg
169 able and effective structure modification in ankylosing spondylitis, the data strongly suggest a bene
170                                  As in human ankylosing spondylitis, the MHC was the major permissive
171          To identify susceptibility loci for ankylosing spondylitis, we undertook a genome-wide assoc
172       There are few effective treatments for ankylosing spondylitis, which causes substantial morbidi
173 atibility complex genes in predisposition to ankylosing spondylitis, which will be summarized here.
174  and women differ in their susceptibility to ankylosing spondylitis, with about 2.5 men affected for
175 de over 90% of the overall susceptibility to ankylosing spondylitis, with about half of the genetic c
176  with unlike conformations in differentially ankylosing spondylitis-associated subtypes) must not be
177  initiate autoimmune damage in patients with ankylosing spondylitis-associated subtypes.
178 espect to understanding the genetic basis of ankylosing spondylitis.
179 pus erythematosus, rheumatoid arthritis, and ankylosing spondylitis.
180 ists are effective for signs and symptoms of ankylosing spondylitis.
181 s and spinal deformities similar to those in ankylosing spondylitis.
182 en shown to be effective in the treatment of ankylosing spondylitis.
183  dissection of the genetic susceptibility to ankylosing spondylitis.
184 otential role in delaying the progression of ankylosing spondylitis.
185 itis and to attenuate spinal inflammation in ankylosing spondylitis.
186 antagonists can prevent structural damage in ankylosing spondylitis.
187 b were also effective in phase III trials in ankylosing spondylitis.
188 thritis can be asymptomatic, as in classical ankylosing spondylitis.
189 or (p75):Fc fusion protein, in patients with ankylosing spondylitis.
190 , and sustained improvement in patients with ankylosing spondylitis.
191  in Sardinia, seem not to be associated with ankylosing spondylitis.
192 ondyloarthropathies, psoriatic arthritis and ankylosing spondylitis.
193 children or siblings of female patients with ankylosing spondylitis.
194 rials of secukinumab in patients with active ankylosing spondylitis.
195 ording to the modified New York criteria for ankylosing spondylitis.
196 s Crohn's disease, rheumatoid arthritis, and ankylosing spondylitis.
197 e epistatic association of both molecules in ankylosing spondylitis.
198 icrobiome are associated with development of ankylosing spondylitis.
199 orm of axial spondyloarthropathies, which is ankylosing spondylitis.
200 -7.0) for psoriasis, psoriatic arthritis, or ankylosing spondylitis.
201 -B27 subtypes differentially associated with ankylosing spondylitis.
202 inflammatory diseases, notably psoriasis and ankylosing spondylitis.
203 th inflammatory bowel disease, psoriasis and ankylosing spondylitis.
204 f exercise and nonpharmacologic therapies in ankylosing spondylitis.
205 on may be of benefit to select patients with ankylosing spondylitis.
206  psoriatic arthritis, reactive arthritis, or ankylosing spondylitis.
207 rmatomyositis; 16 had scleroderma; eight had ankylosing spondylitis; five had juvenile RA; three had

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top